This article will explore the importance of rare disease market research.
For Pharma · Biotech · Medical Device
Rare disease market research for pharma and biotech
Reaching physicians and patients in rare disease is not a volume problem — it is a verification problem. Therefore, MedPanel focuses on validated recruitment strategies built specifically for complex and ultra-rare conditions. As a full-service rare disease market research firm, we provide pharma, biotech, and medical device companies with direct, verified access to the specialists, patients, and caregivers who matter most to their development and commercialization programs. In addition, every panel member is credentialed rather than self-reported, while every protocol is designed to be IRB-ready from day one.
What is rare disease market research — and why does it require a specialist?
Standard market research infrastructure was built for common conditions. As a result, off-the-shelf panels often rely on self-reported demographics, recruit from general consumer pools, and cannot always guarantee clinical specificity. However, in rare disease — where a condition may affect fewer than 200,000 people in the United States, where treating physicians number in the hundreds globally, and where patients often go years without a confirmed diagnosis — this generalized approach becomes significantly less effective.
Rare disease market research is the systematic collection of insights from verified rare disease specialists, affected patients, and their caregivers to inform drug development, regulatory strategy, market access, and commercial planning. In practice, effective research in this area requires a dedicated rare disease panel, disease-specific recruitment expertise, and the ability to conduct compliant studies across multiple geographies. Therefore, MedPanel has developed each of these capabilities specifically to support the unique demands of the rare disease environment.
- 01
A dedicated rare disease panel — credentialed specialists across hematology, neurology, metabolic disease, and genetics. - 02
Disease-specific recruitment expertise — researchers who understand therapeutic context and community sensitivity. - 03
Cross-geography compliance — IRB-ready protocols for studies spanning NA, EU, and Asia-Pacific. - 04
Verified primary-source credentials — every specialist is validated, not asked to self-identify.
MedPanel’s rare disease research services
Our rare disease market research services support the full development and commercialization lifecycle. In addition, whether you require rapid quantitative data collection or deeper qualitative exploration, our research team designs studies that deliver findings suitable for steering committees, advisory panels, and regulatory discussions.
01 · Quantitative
Physician & KOL Surveys
Quantitative surveys are conducted with verified rare disease specialists — including hematologists, neurologists, metabolic disease specialists, geneticists, and other experienced clinicians — recruited through MedPanel’s proprietary credentialed panel. Furthermore, all results are field-cleaned and delivered with detailed demographic breakdowns to support reliable research analysis.
02 · Qualitative
In-Depth Interviews (IDIs)
One-on-one qualitative interviews are conducted with treating physicians, investigators, and patient advocates to generate deeper clinical and market insights. In particular, IDIs are highly effective when organizations need to understand treatment decision logic, unmet needs, or early-stage product concepts in greater detail.
03 · Expert
Virtual Advisory Boards
Structured expert consultations bring together rare disease thought leaders around specific scientific, clinical, or commercial questions. In addition, MedPanel facilitates advisory boards using IRB-compliant protocols and experienced moderators with specialized expertise in rare disease research environments.
04 · Economic
Health Economics & Outcomes Research
Payer, formulary decision-maker, and outcomes-focused research supports health technology assessments, value dossiers, and reimbursement strategies for rare disease therapies. Additionally, MedPanel helps organizations generate evidence-based insights that strengthen market access and healthcare decision-making processes.
05 · Patient voice
Patient & Caregiver Studies
Patients and caregivers are primary stakeholders in rare disease development, particularly in patient-reported outcome validation, burden-of-disease assessments, access research, and patient preference studies that support regulatory and commercial objectives. In addition, MedPanel recruits verified rare disease patients and caregivers through our global rare disease network to support compliant and insight-driven research initiatives.
06 · Longitudinal
Observational & Longitudinal Research
For programs that require repeated data collection over time — including disease progression tracking, treatment pattern analysis, and quality-of-life outcome research — MedPanel designs longitudinal studies supported by stable participant recruitment and IRB-maintained research protocols. Furthermore, our approach helps ensure continuity, compliance, and reliable long-term data collection throughout the study lifecycle.
Disease areas we cover
MedPanel conducts rare disease market research across a broad range of therapeutic categories. In addition, our verified specialist panel and rare disease patient recruitment network support studies involving physicians, patients, caregivers, and advocacy communities across multiple specialized condition areas.
01
Rare hematologic disorders
02
Rare neurological & neuromuscular diseases
03
Rare metabolic & lysosomal storage disorders
04
Rare oncology & hematologic malignancies
05
Rare immunological & autoimmune conditions
06
Rare pediatric & genetic diseases
07
Rare pulmonary conditions
08
Rare cardiovascular & cardiomyopathy conditions
09
Rare endocrine & metabolic diseases
10
Rare ophthalmological conditions
11
Rare dermatological conditions
If your disease area is not listed, contact us — our recruitment team has fielded studies in more than 70 rare conditions globally.
Why pharma and biotech choose MedPanel
01
Verified Panel — Not Self-Reported
MedPanel’s rare disease specialist panel is credentialed against primary source data rather than relying solely on self-reported job titles. For example, when a respondent identifies as a treating hematologist for Paroxysmal Nocturnal Hemoglobinuria, that expertise is independently validated through professional sources. As a result, this distinction helps ensure that research findings more accurately reflect real-world clinical experience and decision-making.
02
Global Rare Disease Reach
Rare disease development is an international endeavor. Therefore, MedPanel recruits and fields studies across North America, Europe, and select Asia-Pacific markets to support global research objectives. In ultra-rare conditions with single-digit global prevalence, international reach is not simply beneficial — it is often essential for achieving meaningful sample sizes and reliable study outcomes.
03
IRB-Ready Protocols
Every MedPanel study involving patients or caregivers is designed to meet IRB submission requirements from the outset. In addition, our research team includes professionals experienced in rare disease clinical compliance and regulated research environments. As a result, we can move efficiently from project brief to protocol development while maintaining strong regulatory and operational standards.
04
Rare Disease Specialists on Staff
MedPanel is not a generalist panel company with a rare disease product layer. Instead, our research team includes project managers and research designers who work exclusively in rare and specialty disease research. As a result, our team understands the therapeutic context, recruitment limitations, and the level of sensitivity required when engaging rare disease patient communities and healthcare specialists.
Supporting resources
Before or after speaking with our team, you may find these resources useful.
Our founding mission, leadership team, and approach to rare disease research.
Our research process from brief to deliverable.
Examples of rare disease research projects across therapeutic areas.
Our IRB protocol standards and participant protection practices.
Reach our team directly with a project inquiry.
Schedule a consultation
Talk to a rare disease research specialist
Rare disease programs often move on compressed timelines, and early research design decisions can have significant downstream implications. Therefore, MedPanel’s rare disease research specialists are available to review your brief, advise on appropriate study design strategies, and provide realistic timelines and budget guidance tailored to your program requirements.
Prefer to send a brief first? Email our research team at info@medpanel.com with your therapeutic area, target respondents, and research objectives.